Coya Therapeutics, Inc.
COYA
$6.73
$0.233.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.57% | -39.87% | -40.79% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.57% | -39.87% | -40.79% | -- | -- |
| Cost of Revenue | 19.55% | 88.20% | 115.68% | 38.94% | 62.48% |
| Gross Profit | -833.21% | -701.98% | -1,760.00% | 76.12% | 79.86% |
| SG&A Expenses | 12.50% | 6.36% | 13.43% | 43.60% | 57.68% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -17.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.37% | 44.13% | 55.50% | 88.40% | 99.14% |
| Operating Income | -120.70% | -96.04% | -134.02% | -1.40% | -3.07% |
| Income Before Tax | -124.61% | -86.40% | -114.77% | 19.30% | 27.66% |
| Income Tax Expenses | -199.50% | -199.50% | -199.50% | -- | -- |
| Earnings from Continuing Operations | -101.38% | -66.31% | -86.29% | 13.45% | 22.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.38% | -66.31% | -86.29% | 13.45% | 22.07% |
| EBIT | -120.70% | -96.04% | -134.02% | -1.40% | -3.07% |
| EBITDA | -121.03% | -96.31% | -134.53% | -1.41% | -3.13% |
| EPS Basic | -61.00% | -20.62% | -19.93% | 67.57% | 76.90% |
| Normalized Basic EPS | -87.23% | -45.12% | -46.09% | 68.83% | 77.86% |
| EPS Diluted | -61.00% | -20.62% | -19.93% | 67.57% | 76.90% |
| Normalized Diluted EPS | -87.23% | -45.12% | -46.09% | 68.83% | 77.86% |
| Average Basic Shares Outstanding | 29.13% | 39.27% | 49.93% | 72.72% | 102.64% |
| Average Diluted Shares Outstanding | 29.13% | 39.27% | 49.93% | 72.72% | 102.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |